COVID-19: FDA Issues Template for Over-the-Counter At-Home Testing

30 July 2020 Blog
Authors: Kyle Y. Faget David L. Rosen Nathan A. Beaver Paul Joseph
Published To: Health Care Law Today Coronavirus Resource Center:Back to Business

As the U.S. continues to struggle to make COVID-19 tests available for symptomatic and asymptomatic individuals, FDA’s position regarding COVID-19 test standards is evolving.  The FDA’s pivot is possibly a response to industry’s plea to facilitate the type of large-scale screening and testing needed to reopen the country.  Last week, the FDA took steps to make testing more accessible to asymptomatic individuals, including with new guidance and authorizations for pooled testing and for testing of asymptomatic individuals.  With the FDA’s latest guidance, it is also taking steps to make testing available on an over-the-counter basis.  Such steps clear the way for companies to continue to innovate in new ways with a clearer path towards FDA authorization. 

As previously reported, the FDA recently began to identify a path for screening of asymptomatic individuals, and on July 24, 2020 the FDA authorized the first diagnostic test for people who do not have COVID-19 symptoms or who have no reason to suspect COVID-19 infection.  A second authorization for pooled sample testing was also released; the first authorization for pooled sample testing was issued on July 18, 2020.  Despite these gains, barriers to testing continue.  For example, pursuant to the emergency use authorizations (EUAs) issued by the FDA to date, all COVID-19 testing must be performed by certified laboratories and may only be conducted pursuant to an order by a healthcare provider (apart from a small number of point-of-care tests). 

On July 29, 2020, FDA signaled further efforts to allow more expansive testing in its release of its statement, Coronavirus (COVID-19) Update: FDA Posts New Template for At-Home and Over-the-Counter Diagnostic Tests for Use in Non-Lab Settings, Such as Homes, Offices or Schools, that includes a new template for commercial developers to assist with development and submission of EUA requests for COVID-19 diagnostic tests that can be performed entirely at home or in other settings besides a certified laboratory, such as offices or schools, and that could be available without a prescription.  As FDA Commissioner Stephen M. Hahn, M.D. was quoted saying in the statement, the tests contemplated by the template are “intended to help get tests to market that are simple enough to use at home, similar to a pregnancy test.”

The template includes important recommendations to developers regarding validation, including (1) when a sample is to be collected and analyzed, and results are to be returned without the need to send a sample to a certified laboratory for analysis; and (2) for tests that are intended to be made available over-the-counter without a prescription.  The template also outlines the recommended sensitivity levels for these types of tests signaling that lower sensitivity levels will be permitted, as compared to laboratory tests, because the benefits of broader testing will outweigh the risks posed by a lower sensitivity test.

Impact

Once authorizations are issued for over-the-counter testing, tests could be bought at a local drug store without a prescription and performed at home, which would be a “game changer” for those hoping to engage in broad scale test screening, such as employers who are continuing to implement their back-to-work action plans.  To date, such efforts have been met with multiple hurdles, including how to order such tests to be compliant with existing EUAs.  An at home test akin to a pregnancy test would solve many of the hurdles faced by those interested in convenient, cost-effective, and widely available testing of asymptomatic individuals.  The FDA’s announcement together with FDA’s recent authorization for testing individuals without known or suspected COVID-19 infection, and its approved use of pooled samples, suggests that FDA is working toward making COVID-19 testing both efficient and widely available.  This approach will also likely have the effect of incentivizing innovation both in testing technology and peripheral applications, such as digital platforms that can digitize, encrypt, transmit, and store testing data.

Companies in all sectors of the economy continue to be impacted by COVID-19. Foley’s here to help our clients effectively address the short- and long-term impacts on their business interests, operations, and objectives. Foley provides insights and strategies across multiple industries and disciplines to provide timely perspective on the wide range of legal and business challenges that companies face conducting business while dealing with the impact of the coronavirus. Click here to stay up to date and ahead of the curve with our key publications addressing today’s challenges and tomorrow’s opportunities. To receive this content directly in your inbox, click here and submit the form. 

This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.

Related Services

Insights

Top Five New Telehealth Policies in Medicare 2021 in Physician Fee Schedule
02 December 2020
Health Care Law Today
IMMEX Highlights – Sub-maquila Operations
02 December 2020
Dashboard Insights
Podcast Episode 24: Steve Cade, Partner
01 December 2020
Foley Career Perspectives
European Data Protection Board Issues Recommendations for Exports of Personal Data From the European Economic Area
01 December 2020
Privacy, Cybersecurity & Technology Law Perspectives
HCCA San Francisco Regional Conference
04 December 2020
Virtual Conference
Webinar: Massachusetts Paid Family and Medical Leave 2021
02 December 2020
Webinar
CTeL Digital Health Summit 2020
01-04 December 2020
Virtual Conference
Virtual CLE Week
Every Tuesday & Thursday from December 1 - 17 2020
Webinar